tetano
Editor, Senior Moderator
Vaccine
. 2021 May 13;S0264-410X(21)00555-7.
doi: 10.1016/j.vaccine.2021.05.004. Online ahead of print.
Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States
Jessie R Chung[SUP] 1 [/SUP], Brendan Flannery[SUP] 2 [/SUP], Sara S Kim[SUP] 3 [/SUP], Manjusha Gaglani[SUP] 4 [/SUP], Chandni Raiyani[SUP] 5 [/SUP], Edward A Belongia[SUP] 6 [/SUP], Huong Q McLean[SUP] 7 [/SUP], Mary Patricia Nowalk[SUP] 8 [/SUP], Richard K Zimmerman[SUP] 9 [/SUP], Michael L Jackson[SUP] 10 [/SUP], Lisa A Jackson[SUP] 11 [/SUP], Emily T Martin[SUP] 12 [/SUP], Arnold S Monto[SUP] 13 [/SUP], Manish Patel[SUP] 14 [/SUP]
Affiliations
Abstract
Introduction: Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE.
Methods: We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE.
Results: We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups.
Conclusion: Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings.
. 2021 May 13;S0264-410X(21)00555-7.
doi: 10.1016/j.vaccine.2021.05.004. Online ahead of print.
Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States
Jessie R Chung[SUP] 1 [/SUP], Brendan Flannery[SUP] 2 [/SUP], Sara S Kim[SUP] 3 [/SUP], Manjusha Gaglani[SUP] 4 [/SUP], Chandni Raiyani[SUP] 5 [/SUP], Edward A Belongia[SUP] 6 [/SUP], Huong Q McLean[SUP] 7 [/SUP], Mary Patricia Nowalk[SUP] 8 [/SUP], Richard K Zimmerman[SUP] 9 [/SUP], Michael L Jackson[SUP] 10 [/SUP], Lisa A Jackson[SUP] 11 [/SUP], Emily T Martin[SUP] 12 [/SUP], Arnold S Monto[SUP] 13 [/SUP], Manish Patel[SUP] 14 [/SUP]
Affiliations
- PMID: 33994240
- DOI: 10.1016/j.vaccine.2021.05.004
Abstract
Introduction: Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE.
Methods: We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE.
Results: We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups.
Conclusion: Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings.